Which drug wins? trial pits terlipressin against octreotide for kidney crisis

NCT ID NCT07460908

Completed Disease control Sponsor: Lahore General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two medicines, terlipressin and octreotide, for treating hepatorenal syndrome—a serious kidney complication of advanced liver disease. Sixty adults aged 30 to 70 will receive one of the drugs, and doctors will check kidney function after 48 hours to see which works better. The goal is to find a more effective treatment to improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: terlipressin and octreotide
What this could lead to: If one drug works better, it could become the preferred treatment for hepatorenal syndrome, helping more patients recover kidney function quickly.
What could go wrong: This is a small, single-center trial with only 60 participants. Results may not apply to all patients, and neither drug may prove clearly superior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATORENAL SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury hepatorenal syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATORENAL SYNDROME

Contacts and locations

Locations

Lahore General Hospital, Lahore

Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.